Plenary Session – Global Development in Biotechnology
Date: 24 July (Wednesday) 9:00 – 12:05 Venue: 3F, Bldg. A, CTBC Financial Park, Ballroom A
HEAD OF LIFE SCIENCE & HEALTHCARE RELATIONSHIP BANKING
Silicon Valley Bank
Katherine Andersen serves as Head of Life Science & Healthcare Relationship Banking at SVB. She also sits on the Board of Directors for SVB's Joint Venture in China, SPD Silicon Valley Bank. Prior to SVB, Katherine was a Senior Vice President for Wells Fargo Bank leading the Life Sciences business development and relationship management efforts for the New England region. Before that, she was a Director at Wells Fargo Capital Finance focused on front-end business development and underwriting of structured loans. Prior to Wells, she held various positions across mergers and acquisitions, finance, equity derivatives, audit, and management while at Affiliated Managers Group, Merrill Lynch, GE Corporate Audit Staff and GE Capital.
Katherine has a bachelor’s degree in finance and economics from Virginia Tech. She has also completed Dartmouth’s Tuck Executive Leadership and Strategic Impact Program, Wells Fargo’s Transformational Leadership Program, the Program on Negotiation at Harvard Law School and the GE Capital Financial Management Program.
Away from work, Katherine serves on the Finance Advisory Board for Virginia Tech, the Advisory Board for WEST (Women in the Enterprise of Science & Technology), and as Chairperson for the American Cancer Society’s Hope Lodge Corporate Council. She also enjoys endurance sports, traveling with her family, and baking epic birthday cakes for her three kids.
Session Speech Title & Synopsis: Asia’s Emerging Role in Global Life Science & Healthcare
Biopharma investments lead the way! Whether considering investments into Asia’s publicmarkets or private markets or investing into the US – Biopharma comes out consistently as theleading Life Science & Healthcare subsector in terms of deals and invested capital. Additionally, it should be no surprise that China’s strong tech sector has developed an interest into the space and will bring their desire for digital solutions with it – potentially indicating more financings with Diagnostics/Tools and Digital Health in the future. When considering Asia on the global stage, it remains a strong competitor due to its evolving population – both talent and growing middle class, and with the establishment of HKEX new IPO’s rules, it will continue to be an attractive market for innovators.